{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:07:07Z","timestamp":1778688427597,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"4_suppl","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To prospectively observe second-line treatment strategies, their clinical outcomes, and treatment costs in patients with glaucoma or ocular hypertension (OH) in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were recruited between 1998 and 2000 in 37 centers and were followed for up to 2 years. Outcomes were numbers of and reasons for treatment changes, changes in clinical parameters (intraocular pressure [IOP] levels, visual field defects, and optic nerve excavation), and direct medical costs associated with glaucoma management in patients receiving monotherapy or combination therapy. This article reports results of an interim analysis of 1-year follow-up data for patients having at least two contacts with a study ophthalmologist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Data were analyzed for 283 patients and 549 treated eyes. Ocular hypotensive monotherapy was used as first-line therapy in 92.0% of eyes. Second-line treatment was initiated an average of 3.4 \u00b1 0.5 years after diagnosis, primarily due to insufficient IOP control (62.8%). Mean IOP reductions after 1 year of second-line therapy were 3.0 mmHg in eyes treated with latanoprost monotherapy versus 2.1 mmHg in those receiving beta-blocker monotherapy (p=0.02) and 5.4 mmHg in eyes treated with the latanoprost + timolol combination versus 4.1 mmHg in those receiving combination therapies that did not include latanoprost (p=0.01). Although second-line treatment with latanoprost was more costly than treatment with beta blockers, the average daily cost for latanoprost monotherapy was similar to that for patients who failed beta-blocker monotherapy, and latanoprost + timolol was less costly than therapeutic combinations without latanoprost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Insufficient IOP control is the main reason for changing first-line treatment in patients with glaucoma or OH. After 1 year, second-line treatment with latanoprost, as monotherapy or combined with timolol, provides superior IOP control at an acceptable cost.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/112067210301304s02","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:34:04Z","timestamp":1516322044000},"page":"5-20","source":"Crossref","is-referenced-by-count":16,"title":["Naturalistic, Prospective Study of Glaucoma and Ocular Hypertension Treatment in France: Strategies, Clinical Outcomes, and Costs at 1 Year"],"prefix":"10.1177","volume":"13","author":[{"given":"J-F.","family":"Rouland","sequence":"first","affiliation":[{"name":"Ophthalmology Service, Regional and University Hospital Center, Claude Huriez Hospital, Lille"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Le Pen","sequence":"additional","affiliation":[{"name":"Dauphine University of Paris, Paris - France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Ophthalmologists of the Glaucoma Study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,7,1]]},"reference":[{"key":"bibr1-112067210301304S02","unstructured":"Direction G\u00e9n\u00e9rale de la Sant\u00e9. L'evaluation de l'impact d'un medicament sur la sant\u00e9 des populations et la sant\u00e9 publique. Rapport du Groupe Technique National de D\u00e9finition des Objectifs: \u00e9laboration de la loi relative \u00e0 la politique de sant\u00e9 publique. Available at: http:\/\/www.sante.gouv.fr\/htm\/dossiers\/losp\/accueil.htm. Accessed March 27, 2003."},{"key":"bibr2-112067210301304S02","first-page":"81","volume-title":"Guide pour les glaucomes.","author":"European Glaucoma Society","year":"1999"},{"key":"bibr3-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810293391808"},{"key":"bibr4-112067210301304S02","first-page":"48","volume-title":"La sant\u00e9 en France 2002.","year":"2002"},{"key":"bibr5-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.829"},{"key":"bibr6-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"bibr7-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00223-2"},{"key":"bibr8-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"bibr9-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)76896-5"},{"key":"bibr10-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.714"},{"key":"bibr11-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"bibr12-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1177\/112067210301304S06"},{"key":"bibr13-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.323.7326.1401"},{"key":"bibr14-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.5.551"},{"key":"bibr15-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01075-8"},{"key":"bibr16-112067210301304S02","first-page":"1057","volume":"23","author":"Baudouin C.","year":"2000","journal-title":"J Fr Ophtalmol"},{"key":"bibr17-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30798-1"},{"key":"bibr18-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30749-5"},{"key":"bibr19-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30750-1"},{"key":"bibr20-112067210301304S02","volume-title":"Nomenclature g\u00e9n\u00e9rale des actes professionnels et nomenclature g\u00e9n\u00e9rale des actes de biologie m\u00e9dicale","year":"2002"},{"key":"bibr21-112067210301304S02","unstructured":"Site officiel du Programme de M\u00e9dicalisation des Syst\u00e8mes d'Information (PMSI). Available at: www.atih.sante.fr\/pmsi. Accessed January 15, 2003."},{"key":"bibr22-112067210301304S02","first-page":"233","volume":"24","author":"Rouland J.F.","year":"2001","journal-title":"J Fr Ophtalmol"},{"key":"bibr23-112067210301304S02","volume-title":"Vidal 2002: Le dictionnaire.","year":"2002"},{"key":"bibr24-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.3310\/hta3020"},{"key":"bibr25-112067210301304S02","first-page":"S271","volume":"8","author":"Shaya F.T.","year":"2002","journal-title":"Am J Manag Care"},{"key":"bibr26-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00235-4"},{"key":"bibr27-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/55.3.272"},{"key":"bibr28-112067210301304S02","first-page":"S255","volume":"8","author":"Dasgupta S.","year":"2002","journal-title":"Am J Manag Care"},{"key":"bibr29-112067210301304S02","first-page":"S262","volume":"8","author":"Spooner J.J.","year":"2002","journal-title":"Am J Manag Care"},{"key":"bibr30-112067210301304S02","doi-asserted-by":"publisher","DOI":"10.1007\/s004170050165"},{"key":"bibr31-112067210301304S02","first-page":"163","volume-title":"Primary open-angle glaucoma: differences in international treatment patterns and costs.","author":"Rouland J-F","year":"1999"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210301304S02","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/112067210301304S02","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:39:18Z","timestamp":1777405158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/112067210301304S02"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":31,"journal-issue":{"issue":"4_suppl","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1177\/112067210301304S02"],"URL":"https:\/\/doi.org\/10.1177\/112067210301304s02","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}